LIFEVANTAGE CORP Capital Expenditures Incurred but Not yet Paid
LIFEVANTAGE CORP (LFVN) reported Capital Expenditures Incurred but Not yet Paid of $0 for the 6-month period ending 2021-12-31, per its 10-Q filed 2022-02-01.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2022-02-01
- 2021-12-31: Capital Expenditures Incurred but Not yet Paid 6 month $0.00.
- 2020-12-31: Capital Expenditures Incurred but Not yet Paid 6 month $1.35M.
- 2019-12-31: Capital Expenditures Incurred but Not yet Paid 6 month $0.00.
| Period end | Capital Expenditures Incurred but Not yet Paid 6 month |
|---|---|
| 2021-12-31 | $0.00 10-Q · filed 2022-02-01 |
| 2020-12-31 | $1.35M 10-Q · filed 2022-02-01 |
| 2019-12-31 | $0.00 10-Q · filed 2021-02-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |